FDA '522' Guidance: 15-Month Deadline To Comply With Postmarket Order
This article was originally published in The Gray Sheet
Executive Summary
The agency has issued a final guidance on Sec. 522 postmarket study orders about five years after a draft version. In the interim, Congress stipulated a 15-month deadline for companies to start the FDA-mandated studies, a requirement emphasized in the new document.
You may also be interested in...
In Case You Missed It: Top 10 Gray Sheet Stories In May
Our reporting on a halted Medtronic stent-graft trial was the most popular online story last month in The Gray Sheet. Also attracting significant attention in May: coverage of the big regulatory changes afoot in Europe, and the growing efforts by FDA leadership to push forward with an envisioned "national evaluation system" for devices.
Senate Seeks Performance Data From FDA On De Novos, Postmarket Surveillance
A Senate panel directs FDA to meets its statutory deadlines for de novo reviews and device risk classifications of devices, and requests data on those programs – as well as for the agency's postmarket device surveillance activities – in a 2017 appropriations bill.
Warning Letter: Exoskeleton Firm Dodged Communication With FDA Over Postmarket Study, Failed To Assemble Surveillance Plan
An FDA warning letter sent to Argo Medical Technologies, now named ReWalk Robotics, outlines the company's failure to conduct mandatory postmarket surveillance activities on its ReWalk bionic walking assistance system. The missive to Argo also lays out a timeline of events that describes how the agency chased after the company.